Literature DB >> 1233256

Brain concentrations of phenytoin, phenobarbitone and primidone in epileptic patients.

G W Houghton, A Richens, P A Toseland, S Davidson.   

Abstract

Plasma, brain, lumbar CSF, skeletal muscle, skin and bone concentrations of phenytoin, phenobarbitone and primidone have been measured in specimens from patients undergoing temporal lobectomy for chronic epilepsy. A good correlation was found between the plasma and brain concentrations of each drug. Similarly, a good correlation was found between the plasma and CSF concentrations of each drug. Assuming that CSF is an ultrafiltrate of plasma, the percentage of phenytoin, phenobarbitone and primidone which was unbound in plasma was 10-14%, 43% and 81% respectively. Skeletal muscle concentrations of phenytoin and phenobarbitone and the skin concentration of phenytoin, also correlated with the plasma concentrations, but the remaining tissues did not give significant correlations.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233256     DOI: 10.1007/bf00613432

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

2.  The distribution of barbiturates in the human body.

Authors:  R L ANDREW; L G NEUBAUER
Journal:  Analyst       Date:  1947-01       Impact factor: 4.616

3.  Urinary excretion of phenobarbitone after a single large dose.

Authors:  A THOMPSON
Journal:  Lancet       Date:  1950-01-14       Impact factor: 79.321

4.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

5.  Anticonvulsant drugs in human epileptogenic brain. Correlation of phenobarbital and diphenylhydantoin levels with plasma.

Authors:  A L Sherwin; A A Wisen; C D Sokolowski
Journal:  Arch Neurol       Date:  1973-08

6.  Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital.

Authors:  F Vajda; F M Williams; S Davidson; M A Falconer; A Breckenridge
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

7.  Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.

Authors:  I Odar-Cederlöf; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

8.  Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.

Authors:  L Lund; A Berlin; K M Lunde
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

9.  Surgical treatment of drug-resistant epilepsy due to mesial temporal sclerosis. Etiology and significance.

Authors:  M A Falconer; D C Taylor
Journal:  Arch Neurol       Date:  1968-10

10.  Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures.

Authors:  L Lund
Journal:  Arch Neurol       Date:  1974-11
View more
  16 in total

Review 1.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

2.  Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier.

Authors:  J T Gilman; P Gal
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 3.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 4.  Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.

Authors:  J T Gilman
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 5.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

Review 7.  Rational usage of therapeutic drug monitoring in antiepileptic treatment.

Authors:  H Bartels
Journal:  Eur J Pediatr       Date:  1980-05       Impact factor: 3.183

8.  Brain concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients.

Authors:  M L Friis; J Christiansen; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

Review 9.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

10.  Differences between the concentrations of antiepileptic drugs in normal and pathological human brain.

Authors:  V A Sironi; L Ravagnati; G Ettorre; G P Cabrini; F Marossero
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.